Clinical Research Study: IgA Nephropathy

ADU-CL-19 is a Phase 1, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of **BION-1301** in Healthy Volunteers and Adults with IgA Nephropathy. The primary objective of the trial is to assess the safety, pharmacokinetics and pharmacodynamics of **BION-1301** in healthy volunteers and patients with IgAN.

In Part 3 of the trial, patients with IgAN will be randomized into two cohorts receiving **BION-1301** at differing doses and frequency in an open-label manner. Enrolled patients will receive three months of dosing with **BION-1301** (IV formulation) and three months of follow-up. The trial duration is expected to be 24 weeks with sites in both the US and UK. Patients enrolled in Part 3 of the study may be eligible to continue dosing for up to 24 months through participation in an Open Label Extension study the sponsor is opening.

You may qualify to participate in the trial if you meet the following Key Inclusion Criteria (other criteria will apply):

- Male or Female ≥18 years old
- Diagnosis of IgAN verified by biopsy taken within the last 10 years
- eGFR > 45 mL/min per 1.73 m^2 OR 30-45 mL/min per 1.73 m^2 if kidney biopsy performed within two years prior to Day 1 with no evidence of fibrosis
- Urine protein ≥ 0.5 g/24h; OR UPCR ≥ 0.5 g/g (or ≥ 50 mg/mmol)
- On a stable dose of ACE and ARBs for >3 months

If you are an adult patient with IgAN who meets these eligibility criteria and are interested in participating in this study, additional information may be found on ClinicalTrials.gov (Identifier: **NCT03945318**) and https://www.chinooktx.com/patients/iga-nephropathy/.